7 research outputs found
Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmonary arterial hypertension patients with severe or rapidly developing disease, some patients refuse this treatment. This study aimed to understand, directly from patients with pulmonary arterial hypertension, why pPCY was refused and, in some cases, later accepted. Interviews were conducted with 25 pulmonary arterial hypertension patients who previously refused pPCY therapy (Group A: Refused/Never initiated (nâ=â9) and Group B: Refused/Initiated (nâ=â16)). Patients in both groups believed that pPCY could improve their symptoms, slow disease progression, and provide them a greater ability to perform activities. Reasons for refusal included concern over side effects and the perceived limitations of pPCY on daily activities. Group A perceived their decision as a balance between quality of life and prolonging life and most acknowledged they would reconsider pPCY if other treatment options were exhausted. Group B cited they initiated therapy due to a worsening of symptoms, disease progression, to improve quality of life, to be there for their family, or a desire to live. Following initiation, Group B indicated their experience met expectations with reduced symptoms, slowed disease progression, and perception of improved survival; concerns related to pPCY were described as manageable. Given the efficacy of pPCY therapy, clinicians should apply knowledge of these findings in clinical practice. Patients noted improvements to parenteral pump technologies to include smaller size, water resistance, and implantability may increase their acceptance of this modality. Development efforts should focus on technologies that increase the acceptance of pPCY when indicated
But where can we buy an ounce of prevention?: Sprawl, access, and fresh fruit and vegetable consumption
Fresh fruit and vegetable consumption (FFV) is integral to a healthy diet and increased longevity, yet 25.8 million Americans live in areas of restricted access, with under-resourced communities particularly vulnerable. To consider how immediate environment influences FFV, this study uses the Behavioral Risk Factor Surveillance System (BRFSS) survey (N = 122,265) to examine the influence of sprawl on FFV consumption. Findings indicate that higher sprawl relates to lower FFV consumption, and this relationship persists net of demographic covariates. Implications offer that social workâs person-in-environment approach can increase FFV access in under-resourced communities.Journal Articl
Realâworld evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Realâworld Evidence Working Group
Abstract This manuscript on realâworld evidence (RWE) in pulmonary hypertension (PH) incorporates the broad experience of members of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative RealâWorld Evidence Working Group. We aim to strengthen the research community's understanding of RWE in PH to facilitate clinical research advances and ultimately improve patient care. Herein, we review realâworld data (RWD) sources, discuss challenges and opportunities when using RWD sources to study PH populations, and identify resources needed to support the generation of meaningful RWE for the global PH community